JPH04200475A - Blood processor - Google Patents

Abstract

PURPOSE:To obtain a blood processor having excellent foreign matter removing performance with limited occurrence of leaving, clotting of blood or the like regardless of high blood compatibility and prolonged use by bonding fatty acid and/or a fatty acid derivative to a mesh-like matter made of a polymer compound through a polymer. CONSTITUTION:Blood flows into a filter 1 at an inflow port 5 to be stored in a main pipe 2 and is discharged at a discharge port 3 after the removal of foreign matters with a mesh-like matter 7. The mesh-like matter is made of a high polymer compound with a shape of a bag in which two mesh sheets are sealed on the periphery thereof and fatty acid and/or a fatty acid derivative are bonded thereto through a polymer. An opening of the mesh-like matter 7 is sealed up over the circumference of the main pipe 2 and the blood passing through the filter 1 all passes through the mesh-like matter 7. A structure of bonding a specified polymer derivative to the mesh-like matter 7 lessens damage to blood as caused by the leaving, the clotting of blood and the like thereby achieving a reduction in the clogging of the mesh-like matter 7.

Description

DETAILED DESCRIPTION OF THE INVENTION <Industrial Application Field> The present invention relates to a blood processing device for removing foreign substances such as air bubbles contained in blood during extracorporeal blood circulation, blood transfusion, etc.

<Prior art> In extracorporeal circulation of blood in treatments using artificial dialysis and artificial lungs, and in blood transfusion sets used for blood transfusion, blood processing devices, so-called blood processing devices, are used to remove foreign substances such as impurities contained in blood. A filter is provided to remove foreign matter.

Such a filter for removing foreign substances from blood is required to have high blood compatibility in addition to performance as a filter.
If the filter is made of a material that is not compatible with blood, residual blood and coagulation will occur, damaging the blood and making it impossible to provide good treatment, and in extreme cases, putting the patient in a dangerous situation. Sometimes it happens.

In particular, since filters for removing foreign substances usually use various meshes, residual blood and blood coagulation are likely to occur, and high blood compatibility is required.

Incidentally, the surface properties of the medical device P, including the filter, are an important factor in blood compatibility. Therefore,
Various methods for modifying the surface properties of medical materials have been proposed. For example, in JP-A-63-130069, a fat-soluble vitamin or a fatty acid derivative having a reactive terminal group is used to modify the surface properties of the reactive terminal group. discloses medical instruments in which various base materials are bonded.

<Problem to be solved by the invention> This medical device has the advantage of improving the surface properties of the base material and imparting blood compatibility while fully demonstrating the physical properties of the base material as a medical material. It had excellent effects. However, even though we were able to obtain sufficient blood compatibility with this first method, it is difficult to obtain adequate blood compatibility (particularly in filters for removing foreign bodies, residual blood, blood coagulation, etc. are likely to occur). For applications, greater blood compatibility is required.

An object of the present invention is to solve the problems of the prior art, and has high blood compatibility and is suitable for long-term use.
Another object of the present invention is to provide a blood processing device (filter for removing foreign matter) which has extremely low occurrence of residual blood, blood coagulation, etc., and also has excellent foreign matter removal performance.

<Eleven steps for solving the problem> In order to achieve the above object, the present invention has a housing and a
, a mesh-shaped mesh formed of a polymer compound fixed to the housing, an inlet provided below the housing, a fit outlet provided below the housing, and an upstream side of the outlet. A blood processing device consisting of:

The present invention provides a blood treatment device characterized in that a fatty acid and/or a fatty acid derivative is bonded to the mesh-like material via a polymer.

Further, it is preferable that the polymer has an epoxy group and/or a carboxyl group.

Further, it is preferable that the fatty acid and/or fatty acid derivative is linoleic acid and/or a linoleic acid derivative.

Hereinafter, the blood processing device of the present invention will be explained in detail.

FIG. 1a shows a schematic cross-sectional view of the blood processing device of the present invention.
FIG. 1B shows a schematic cross-sectional view of the processor in a direction orthogonal to FIG. 1A. Note that FIG. 2 is a schematic diagram of the processor in the direction of FIG. 1b.

A blood processing device 1 (hereinafter referred to as filter 1) shown in FIG. 1 is used by being incorporated into a blood circuit of an artificial dialysis machine, an artificial lung, etc., or a blood flow path of a blood transfusion device, etc. , which removes foreign substances contained in the blood that passes through it.

Such a filter 1 basically consists of a housing consisting of a cylindrical main pipe 2, a bottom swallow 4 having a blood discharge L-13, and a lid body 6 having an inlet 5. A mesh-like material 7 is fixed within the main tube 2 for removing foreign substances from the blood. In the use state, this filter 1 is provided with an inlet [ ] 5 on the F side of the housing and an outlet 1 ] 3 below the housing. Inflow []
Reference numeral 5 is provided in the lid 6 of the housing in the direction in which blood flows in a swirling flow from the lid 6 to the inner surface of the main tube 2, that is, in the tangential direction of the inner surface of the lid 6 in a horizontal section of the lid 6.

In such a filter 1, blood flows into the filter 1 from the inlet 5 and is stored in the main pipe 2, and foreign substances such as blood aggregates and air bubbles are removed by the mesh-like material 7.
It is discharged from discharge [-]3.

The mesh-like material 7 is formed from a polymer compound having a bag-like shape in which two semi-elliptic mesh sheets are sealed at their peripheries, and has a structure in which fatty acids and/or fatty acid derivatives are bonded via a polymer. (hereinafter, a combination of a polymer and a fatty acid and/or a fatty acid derivative is referred to as a polymer derivative), and the opening 9 of the mesh-like object 8
is sealed around the entire circumference of the main pipe 2, and is constructed so that all the blood passing through the filter 1 always passes through this mesh-like member 7.

As mentioned above, the mesh-like material 7 is formed from a polymer compound. Applicable polymer compounds include:
Polyester, polypropylene and its derivatives are most preferably used; others include polyvinyl alcohol, partially saponified polyvinyl acetate, ethylene vinyl alcohol copolymer, partially saponified ethylene-vinyl acetate copolymer, and polyacrylic acid. Alternatively, polymethacrylic acid and copolymers thereof, polyhydroxyethyl methacrylate, chitin, chitosan, collagen, polyacrylamide, etc. are also suitably applicable.

In addition, since the filter I of the present invention has a structure in which a predetermined polymer derivative is bonded to such a mesh-like material 7, its excellent blood compatibility prevents damage to blood due to residual blood, blood coagulation, etc. Therefore, clogging of the mesh-like material 7 can be extremely reduced.

In order to properly remove foreign substances contained in the blood, the opening length (longest direction) of the pores of the mesh-like material 7 should be 180 to 30 mm.
It is about 0um. More preferably, the opening length is 200~
By setting it to about 210 μm, foreign substances can be suitably removed without damaging the blood or interfering with the flow of blood, and better results can be obtained. Note that the holes of the mesh-like material applied to the present invention may be formed regularly or irregularly, and the shape thereof does not need to be uniform. .

In addition, the area ratio of such holes in the mesh-like material 7 is not particularly limited, but is set to 40 to 80% in order to effectively remove foreign substances without damaging the blood or obstructing the blood flow.
It is preferable to set it as approximately. More preferably 7 or 50-6
It is about 0%.

There is no particular limit to the thickness of the mesh-like material 7, but the thickness is usually 1.
00-200uI about 11, preferably 120-150
It is about the size of μ river.

Although the shape of the mesh-like object 7 is not limited to the bag shown in the illustrated example, in order to safely and reliably remove foreign substances over a long period of time, the mesh-like object 7 should have a bag-like shape as shown in the illustrated example. is preferred.

In addition, the method of fixing the mesh-like object 7 to the main pipe 2 may be by various known methods such as using various adhesives or heat fusion, depending on the materials of the mesh-like object 7 and the main pipe 2. good.

However, in order to reliably remove foreign substances contained in the blood, it is preferable that the main tube 2 be fixed in such a manner as to completely occlude the main tube 2 with the mesh-like object 7, as shown in the illustrated example.

In the blood treatment device of the present invention, the mesh-like material 7 formed from such a polymer compound is formed by bonding a polymer of a polymer derivative in which a polymer and a fatty acid and/or a fatty acid derivative are bonded. It has a structure.

In other words, the filter 1 of the present invention has a configuration in which a fatty acid and/or a fatty acid derivative is bonded to the mesh-like material 7 made of a polymer compound via a copolymer. ), a large number of fatty acids are bound to the bonding points of able to demonstrate.

In particular, if a fatty acid derivative is used, a molecular chain (derivative part) can be present as a spacer between the fatty acid and the polymer, which can be expected to suppress platelet adhesion. , it is possible to obtain higher blood compatibility, the spacer length can be easily controlled, and stable motility can be obtained.

Furthermore, if the polymer has a functional group that suitably binds to a fatty acid (fatty acid derivative) and a functional group that suitably binds to a polymer compound, which are different from each other, fatty acids and/or fatty acids can be added to the polymer. The amount of derivatives and polymer compounds bound can be easily adjusted. In addition,
Examples of functional groups that suitably bind to fatty acids (fatty acid derivatives) include carboxyl groups, and examples of functional groups that suitably bind to polymeric compounds include epoxy groups and carboxyl groups.

Examples of functional groups possessed by the polymer include epoxy groups, carboxyl groups, aldehyde groups, etc. As mentioned above, epoxy groups and carboxyl groups are preferred examples, and it is preferable to have at least an epoxy group, or both.

Raw material monomers for introducing epoxy groups into polymers include (
Preferred examples include meth)acrylic acid glycidyl esters. On the other hand, (meth)acrylic acid is preferred as a raw material monomer that provides carboxyl groups to the polymer, and esters such as (meth)acrylic acid esters can be used to synthesize polymers with arbitrary compositions. , methyl (meth)acrylate, ethyl (meth)acrylate, propyl (meth)acrylate, isopropyl (meth)acrylate, butyl (meth)acrylate, isobutyl (meth)acrylate, hydroxymethyl (meth)acrylate , and hydroxyethyl (meth)acrylate are suitably applied.

Further, when obtaining a polymer using the above-mentioned monomer, a polymerization initiator such as ceric ammonium nitrate or hydrogen peroxide-ferrous salt may be used.

The weight ratio of units into which epoxy groups are introduced in the polymer is 0.0% based on the amount of glycidyl methacrylate in the (meth)acrylate polymer.
01% by weight to -60% by weight is suitable. If the weight ratio of units into which epoxy groups are introduced exceeds 60% by weight, the polymer tends to gel during synthesis, which is not preferable.
In addition, surface modification is possible if there is one or more epoxy groups in the polymer, but in order to perform good surface modification, the unit for introducing epoxy groups in the polymer must be 0.01% by weight. The above is preferable.

The molecular weight of such a polymer is preferably 500 to 500,000.If the molecular weight of the polymer is within this range,
Even if the number of bonding portions with the aforementioned polymer compound is small, since the surface area of the polymer is large, the effect of connecting the fatty acid and the polymer compound by the polymer is sufficiently exhibited. Specifically, with a low molecular weight of less than 500, it is difficult to efficiently cover the entire surface of the mesh-like material 7 (polymer compound), and with a high molecular weight of more than so'o or ooo, the solubility of the polymer and It becomes difficult to use due to decreased reactivity with the material surface.

In the present invention, such a polymer constitutes a polymer derivative together with a fatty acid and/or a fatty acid derivative, and the two polymers combine with a mesh-like substance 7 (high-molecular compound) to form a mesh-like substance with a fatty acid and/or a fatty acid derivative. Thing 7
It acts as a fatty acid binder and provides good blood compatibility.

In the blood treatment device of the present invention, such fatty acids include unsaturated fatty acids such as elaidic acid, oleic acid, linoleic acid, lylunic acid, arachidonic acid, and eicosapentaenoic acid, or saturated fatty acids such as lauric acid, myristic acid, and pentasilic acid. Among them, linoleic acid, which has good compatibility with blood, is particularly preferred. In addition, in this invention, these fatty acids may be used individually, or may be used as a mixture.

In the present invention, in order to improve blood compatibility,
The fatty acid is preferably bound to the aforementioned polymer as a fatty acid derivative, i.e. a spacer, preferably a hydrophilic spacer. Examples include alkylene glycols having a highly reactive functional group at the end, and preferred are polyethylene glycol diamine, polypropylene glycol diamine, and polytetramethylene glycol diamine having an amino group at the end as a functional group.

For example, when the spacer has an alkylene glycol skeleton, its degree of polymerization (J, which varies depending on the type of alkylene, is preferably about 1 to 100. In particular, as the alkylene glycol, polyethylene glycol and polypropylene Polyethylene glycols with a polymerization degree of 20 to 90 and polypropylene glycols with a polymerization degree of 10 to 50 are particularly preferred.

In the present invention, when a polymer has an epoxy group, this polymer and a fatty acid and/or a fatty acid derivative are graft copolymerized via the epoxy group of the polymer to form a polymer derivative. In addition, when the polymer has an epoxy group and a carboxyl group, this polymer
An acid and/or fatty acid derivative is n? Granod copolymerization is carried out via the carboxyl group of the polymer 1 to form a polymer derivative.

Note that the synthesis reaction Ii of the polymer derivative may be a direct synthesis reaction.

In the present invention, a polymer of such a polymer derivative is combined with a polymer compound that constitutes the mesh-like material 7 described above, thereby forming a filter for removing foreign substances from blood.

Reaction between a polymer derivative and a polymer compound (J, dissolving a polymer derivative in a suitable organic solvent such as acetone, methyl ethyl ketone, di-Azine, tetrahydrofuran, etc.)
This is carried out by adding a Lewis acid catalyst, a basic catalyst, and a polymer compound to this. specifically(
By immersing the mesh-like material 7 in a solution in which a polymer derivative and a catalyst are dissolved, the polymer derivative and the polymer compound forming the mesh-like material 7 are reacted to form a ball.

In addition, examples of the Lewis acid catalyst include boron trifluoride, tin tetrachloride, and zinc chloride, and from the viewpoint of reactivity, boron fluoride is preferable. In addition, as basic catalysts, among alkaline earth metals, hydroxides such as calcium, strontium, barium, radium, lithium hydroxide, sulfur hydroxide to radium potassium hydroxide, rubidium hydroxide, cesium hydroxide, Alkali metal hydroxides such as francium hydroxide are used, and among these, sodium hydroxide is most preferred in terms of solubility and reactivity.

With this configuration, the blood processing device of the present invention makes it possible to reliably remove foreign substances from blood, and also ensures excellent blood compatibility to prevent residual blood, blood coagulation, etc. It is a device that enables safe, clean, and good blood processing with little damage to the blood. First, it is suitably applied to removing foreign matter inside.

<Example> Hereinafter, the present invention will be specifically explained based on Examples.

[Synthesis of linoleic acid macromer 11] Dissolve 20.0 g of linoleic acid in dry benzene at 70 m℃, put it in a flask, and add 1 phosphorus pentachloride in a nitrogen stream F.
4.8 g was added in 5 portions. After stirring at room temperature for 12 hours, rapid flow was continued for an additional 2 hours. Next, benzene, reaction by-products, postboryl trichloride, and hydrogen chloride were distilled off under reduced pressure to obtain 14.0 g of linoleic acid chloride (boiling point IF) 5°C/1.5 mm) Ig, yield 76. %
).

In a flask, add 50.4 g of polyethylene glycol diamine (PGD-40 manufactured by Toshi ■, molecular weight 4114), 1.48 g of triethylamine, and 120 mf of dichloromethane.
f and 3.66 g of linoleic acid chloride in 70 ml of dichloromethane under nitrogen flow and water cooling (0°C).
The solution was slowly added dropwise over 30 minutes. Thereafter, the mixture was stirred for 2 hours while gradually returning to room temperature.

After the reaction, triethylamine hydrochloride, a reaction by-product, was filtered off, triethylamine and dichloromethane were distilled off under reduced pressure, and the residue was dissolved in chloroform Loomβ and diluted with water 1
Washed gently with 00mj2. After separating the organic layer,
After drying with anhydrous sodium sulfate, it was concentrated. This was subjected to flash chromatography on Wakogel C-300A (decomposition eluent: chloroform/methanol - 9/1 volume ratio).
As a result of purification, 13.7 g of purified product was obtained (yield 26%).

Infrared spectroscopy (IR method), proton nuclear magnetic resonance method (
The structure was confirmed by 'H-NMR method) and the absence of linoleic acid and PGD-40 was confirmed by liquid chromatography (GPC mode, eluent THF).

The results of this measurement are shown below.

JR method: 1650cm-'amide carbonyl stretching vibration 1540cm-'amide NH bending vibration 1100cm-
'Ether CO stretching vibration' H-NMR method: δ0.9 ppm linoleic acid -CH.

δ1.3 ppm Linoleic acid -CH, -δ3.7p
pm Polyethylene glycol-0C82CH20- δ5.3ppm Linoleic acid olefin-CH=C
H-GPC method: Retention capacity Purified product 11.4mJ2PGD
-4012゜6mJ2 Linoleic acid 15.1mff [2] Add 0.15 parts by weight of azobisisobutyronitrile and 7.5 parts by weight of methyl methacrylate as a polymerization initiator to the polymer synthetic glass polymerization tube.
parts by weight, 15 parts by weight of glycidyl methacrylate,
3-methacryloxypropyltris(methoxyethoxy)silane (manufactured by Chisso ■) 6 parts by weight, methacryl vx, 5
The polymerization tube was cooled and solidified in liquid nitrogen, and after repeating deaeration, nitrogen substitution, and deaeration using a vacuum pump, the tube was sealed. This was heated in a constant temperature bath at a predetermined temperature for a predetermined time. Thereafter, the container was cooled and opened, and the contents were dissolved in tetrahydrofuran and reprecipitated in methanol to obtain a white polymer (Polymer 1).

Similarly, a polymer containing no methacrylic acid was also synthesized (Polymer 2).

Epoxy equivalents were determined by dissolving these polymers in methyl ethyl ketone and titrating with 0.0 IN perchloric acid/acetic acid solution using ethyltrimethylammonium bromide as a catalyst and crystal violet as an indicator, and the glycidyl methacrylate composition was determined. Ta.

Table 1 below shows the charged monomers, polymerization conditions, and glycidyl methacrylate composition.

Table 1: MMA/GMA/MPTMS/MA = 7.5
/15/6/1.5 (weight ratio) B: MMA/GM^
/MPTMS = 7.5/15/7.5 (weight ratio) MMA: methyl methacrylate GMA nigericidyl methacrylate-1 MPTMS: 3-methacryloxypropyl tris(methoxyethoxy)silane MA: methacrylic acid [3-1 ] Synthesis of polymer derivative I (reaction of linoleic acid macromer and polymer 1) 4.00 g of polymer 1 obtained in the above [2] and 0.0 g of dicyclohexylcarpodiimide were added. 718 g and 100 mβ of a mixed solvent of carbon tetrachloride/acetonitrile (1:1 volume ratio) were placed in a flask, and the
After stirring for several minutes, 12.0 g of carbon tetrachloride/acetonitrile (1:1 volume ratio>20 m, C solution) was gradually added dropwise to the linoleic acid macromer obtained in []] above, and then stirred at room temperature for 60 minutes. After the mixture had evaporated, the mixture was further stirred at 60°C for 60 minutes.

After cooling the reaction contents to room temperature, the contents were filtered through a glass filter (2), and the solvent of the filtrate was lightly distilled off to obtain a yellow, highly viscous crude product.

200 mρ of methanol was added to the obtained crude product, and the mixture was stirred at room temperature for about 30 minutes until there were no lumps, followed by centrifugation, and the supernatant was removed by decantation. After repeating the same operation two more times, vacuum drying
9.63 g of polymer derivative 1 with no Ij was obtained.

[3-II] Synthesis of polymer derivative II (reaction of linoleic acid macromer and polymer 2)
10.0 g of linoleic acid MacVcomer obtained in step 1]
, and benzene/]" HI. (4:3 volume ratio) mixed solvent 80 ml, C was placed in a flask and refluxed for 3 hours under nitrogen atmosphere -vl=.

After the reaction contents were cooled to room temperature, the solvent was lightly distilled off to obtain a yellow, highly viscous crude product. Add 100 mg of the obtained crude product, methanol, and stir at room temperature for about 3
After stirring for 0 minutes until there were no lumps, centrifugation was performed, and the 1-drops were removed by decantation.
After carrying out the same operation twice more, 8.71 g of vacuum-dried Pi-free polymer derivative II was obtained.

[4] Preparation of blood treatment device (bonding of the polymer derivatives ① and II to the mesh-like material 7 made of a polymer compound) Using the mesh-like material 7 having the following physical properties, as shown in FIG. A blood processing device (filter 1) was produced.

Material Polyester thread Diameter 7 lum ± 8
%Opening 208μm±10% Thickness 135μm±
10% mesh 90 mesh/in±5%
Note that the radius of the opening 9 of the mesh-like object 7 thus produced is 18.
2mm, the radius of the occluded side is about 10mm, and the height (
The blood flow direction) was 56.8 mm.

First, sodium hydroxide 0.5 (W/V)% aqueous solution 1
The mesh-like material 7 was soaked in 00 mff for 30 minutes. Next, 0.0% of each of the polymer derivatives I and II.
The mesh-like material 7 was sequentially immersed in a 5 (W/V)% acetone solution and allowed to react at room temperature for 24 hours.

After the reaction is complete, take out the mesh-like material 7, add 2, acetone,
Meshes 7-1 and 7- are thoroughly washed in the order of ethanol and distilled water to remove foreign substances mixed into the blood.
II and 7.

The two types of mesh-like material 7 according to the present invention and the conventional mesh-like material that does not have a polymer derivative were
The following test was conducted by attaching the filter to the filter I (blood processing device) as shown in the figure. In addition, each mesh-like object was fixed to the main pipe 2 by high frequency welding.

[5] Extracorporeal circulation test The rabbit was immobilized on the Kitajima-style immobilization stand.

Next, the hair in the surgical field was trimmed with electric clippers and wiped with alcohol cotton. An incision was made along the midline until it reached the clavicle with scissors, and the right (left) carotid artery was dissected, being careful not to open the fascia and damage the nerves, branch vessels, and surrounding tissues. Next, deeply dissect the 7i (right) facial vein of Mr. M with caution 1 and 2, and insert an indwelling catheter (Surflow manufactured by Terumo@) with a rubber cap for mixed injection filled with heparinized saline of IItJ/mj2. Fixed. Similarly, a catheter was also inserted into the artery and fixed.

The rabbit thus prepared was subjected to a blood circulation circuit as shown in FIG.

That is, the catheter 2 connected to the artery of the rabbit 20
1 was connected to a pump 22, and further, the chamber 23 and the vein of the rabbit 20 were connected with a catheter 25. The pump 22 and the filter 1 are connected by a duplex 26, and this tube 26 communicates with the inlet 27 side of the manometer.
Further, the filter 1 and the chamber 23 communicating with the outside side of the manometer 240 were communicated through a duplex 28 .

As the filter 1 of such a blood circulation circuit, the filter 1 according to the present invention and the conventional filter (blank) are used.
was used to circulate the blood of 20 rabbits, and the variation in platelet counts over time was determined. The platelet count was measured using Sysmex NE-6000 (manufactured by Toa Medical Electronics Co., Ltd.). Further, the blood circulation circuit (including the filter 1) is not subjected to heparin treatment.

The results are shown in Table 2 below and Figure 4.

Note that, in Table 2, the conventional example is shown as a blank, and the blood processing device (7-I Kasa) to which the invention example is applied is shown.

<Effects of the Invention> In the blood processing device of the present invention, fatty acids and/or fatty acid derivatives are bonded to a mesh made of a polymer compound via a polymer, so that the blood treatment device containing the mesh
The coagulability is reduced, the activation of the complement system is inhibited, and platelet mucus is inhibited, which gives the polymer compound stable blood compatibility over a long period of time and prevents damage to the blood. It is possible to remove foreign substances contained in the blood while maintaining a safe and clean condition.

[Brief explanation of the drawing]

FIG. 1a and FIG. 11) are schematic sectional views showing an example of a blood processing device according to the present invention. FIG. 2 is a schematic diagram of the blood processor shown in FIGS. 1a and 1b. FIG. 3 is a conceptual diagram of the blood circulation circuit. FIG. 4 is a graph showing changes in platelet count. Explanation of symbols 1... Filter (blood processor), 2... Main pipe, 3... Discharge inlet, 4... Bottom cover, 5... Inflow port 6... Lid body, 7... ...Mesh-like object, 9...Opening, 20...Rabbit, 21.25...Catheter, 22...Pump, 23...Chamber, 24...Manometer, 26.28... Tube, 27... Manometer patent applicant f) Il'-E Co., Ltd.

Claims (3)

[Claims] (1) a housing, an inlet provided above the housing, and an outlet provided below the housing;
fixed to the housing on the upstream side of the discharge port;
A blood processing device comprising a mesh-like material formed of a polymer compound, the blood processing device comprising a fatty acid and/or a fatty acid derivative bonded to the mesh-like material via a polymer. . (2) The blood treatment device according to claim 1, wherein the polymer has an epoxy group and/or a carboxyl group. (3) The blood treatment device according to claim 1 or 2, wherein the fatty acid and/or fatty acid derivative is linoleic acid and/or a linoleic acid derivative.